No Data
No Data
Inkon Life Technology (300143.SZ): With the introduction of AI-assisted diagnostic system, the clinical detection rate of pulmonary nodules has increased by 32%.
In its investor relations event on July 17th, Inkon Life Technology (300143.SZ) stated that it will further enhance user experience through digitalization. Taking Suzhou Guangci Cancer Hospital as an example, the hospital continues to explore and actively deploy AI applications. In terms of doctor experience, the clinical detection rate of pulmonary nodules increased by 32% and doctors' film reading efficiency improved by 26% through the introduction of an AI-assisted diagnostic system. By reconstructing the patient's image data into a 3D model, doctors can rotate the 3D image from all angles, simulate the surgical procedures before surgery, and plan the optimal surgical path. The application of AI has improved the efficiency and accuracy of diagnosis and treatment. Patient experience improved as well.
Inkon Life Technology (300143.SZ): As of July 10, 2024, the total number of shareholders of the company is 16,475.
Inkong Life Technology (300143.SZ) stated on the investor interaction platform on July 12th that as of July 10, 2024, the total number of shareholders in the company was 16,475.
INKON Life Technology's (SZSE:300143) Earnings Trajectory Could Turn Positive as the Stock Soars 15% This Past Week
This week we saw the INKON Life Technology Co., Ltd. (SZSE:300143) share price climb by 15%. But that doesn't change the fact that the returns over the last three years have been disappointing. In
Inkon Life Technology (300143.SZ) has passed the review of the Shenzhen Stock Exchange Listing Review Center for the application of issuing additional stocks.
Zhittong Finance APP reports that Inkon Life Technology (300143.SZ) announced that it received the approval letter from the Shenzhen Stock Exchange (hereinafter referred to as the "SZSE") Listing Review Center on June 28, 2024, regarding the application for issuing shares to specific objects. The SZSE issuing and listing audit agency has reviewed the company's application documents for issuing shares to specific objects and believes that the company meets the issuance conditions, listing conditions and information disclosure requirements. Subsequently, the SZSE will report to the China Securities Regulatory Commission (hereinafter referred to as the "CSRC") in accordance with regulations.
Inkon Life Technology (300143.SZ) completed the repurchase with a total of 6.1568 million shares repurchased.
Inkon Life Technology (300143.SZ) announced that as of June 27, 2024, the company will use centralized bidding for trading...
Inkon Life Technology (300143.SZ): Cumulative expenditure of 47.8567 million yuan to repurchase 5.5907 million shares.
On June 3rd, Gelonhui reported that Inkon Life Technology (300143.SZ) announced that as of May 31, 2024, the company repurchased 5,590,652 shares of its own stock through a share repurchase dedicated securities account using centralized bidding trading method, accounting for 0.87% of the company's current total share capital (calculated based on the company's total share capital of 642,167,010 shares after the close of trading on June 3, 2024). The highest and lowest transaction prices for the repurchase were 8.90 yuan/share and 8.09 yuan/share, respectively, and the total transaction amount was RMB 47,856,696.96 (excluding transaction fees).
No Data